trending Market Intelligence /marketintelligence/en/news-insights/trending/aE1pi854Evc8y7V6YmpM3Q2 content esgSubNav
In This List

AstraZeneca-Merck's Lynparza gets US FDA priority review in ovarian cancer

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


AstraZeneca-Merck's Lynparza gets US FDA priority review in ovarian cancer

AstraZeneca PLC and Merck & Co. Inc.'s Lynparza was granted priority review in the U.S. as initial maintenance therapy for patients with advanced ovarian cancer.

The U.S. Food and Drug Administration is expected to make a decision on the companies' medicine in the second quarter of the year. If approved, Lynparza, or olaparib, will be available for patients with advanced ovarian cancer who are in complete or partial response to initial treatment with Roche Holding AG's Avastin, or bevacizumab.

As a maintenance treatment, Lynparza would be expected to bolster the effects of Avastin. Data from a phase 3 trial called Paola-1 has already demonstrated that using Lynparza as a maintenance treatment helps extend the lives of patients who have received Roche's drug.

Lynparza is already approved across multiple cancer indications around the world, including in parts of Asia, as well as in the EU. In the U.S., Lynparza is approved as maintenance therapy for women with certain types of ovarian, fallopian tube and peritoneal cancer who benefit from chemotherapy.